No Detail Found!

Clinical Outcomes and Long-Term Effects of Consolidative Radiotherapy in Paediatric Hodgkin's Lymphoma

Author(s)
Syed Muhammad Jawad Zaidi Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,Lahore,Pakistan
Rabia Muhammad Wali Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,Lahore,Pakistan
Naila Inayat Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,Lahore,Pakistan
Sadia Anjum Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,Lahore,Pakistan
Abstract
To evaluate the long-term e ects and disease outcomes of consolidative radiotherapy in paediatric Hodgkin s lymphoma (PHL). Study Design: Descriptive study. Place and Duration of the Study: Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from March to November, 2023. Methodology: This retrospective cohort study was conducted on 91 PHL patients. All patients with the presence of residual disease on interim PET scan received radiation therapy. A standard dose of 19.8 Gy was given as 11 fractions, and boost was given to bulky disease as 10 Gy in 5 fractions. Data regarding patient demographics, disease characteristics, and treatment details were collected from the institutional database. Results: Out of the 91 patients, 73 (80.2%) were male and 18 (19.8%) were female. The overall mean age at presentation was 7.7 ± 3.3 years. High-risk disease was found in 81 (89%), while 44 (48.4%) had stage IV disease. Complete remission was achieved in 70 (76.9%), loss to follow-up in 11 (12.1%), disease progression/relapse in 4 (4.4%), and death during treatment in 6 (6.6%) patients. The ve-year overall survival was 90%, and event-free survival was 76.9%. During treatment, a total of nine patients had moderate-tosevere left ventricular dysfunction, six patients had altered thyroid pro les (hypothyroidism), three developed pulmonary brosis, and one patient developed cerebellar ataxia. Conclusion: There is a good ve-year overall and event-free survival. Cardio toxicity, hypothyroidism, and pulmonary brosis were common long-term chemotherapy / radiotherapy-related side e ects. Prospective randomised controlled trial is needed to reduce dose of radiotherapy by giving it to PET-positive residual disease at the end of treatment rather than at mid-assessment.
Publication Details
Page(s) 778-783
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
Radiotherapy, clinical outcomes, Paediatric Hodgkin s lymphoma
References
Totadri S,Radhakrishnan V,Ganesan TS,Ganesan P,Kannan K,Lakshmipathy KM .2017 .Can radiotherapy be omitted in children with Hodgkin lymphoma who achieve metabolic remission on interim positron emission tomography? Experience of a tertiary care cancer referral center. J Glob Oncol, 009340 : 1-7.
Korholz CM,Parker JL,Balwierz W,Ammann RA,Anderson RA,Attarbaschi A .2022 .Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): A titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. (21), 10(1) : 470-8.
Lo AC,Dieckmann K,Pelz T,Evans EG,Cabillic RE,Vordermark D .2021 .Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer, 10(Suppl 2) : .
Venkatramani R,Kamath S,Wong K,Olch AJ,Malvar J,Sposto R .2014 .Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved eld radiation. Pediatr Blood Cancer, 10(7) : 1277-81.
Kelly KM,Cole PD,Pei Q,Bush R,Roberts KB,Hodgson DC .2019 .Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the children's oncology group. Br J Haematol, 10(1) : 39-48.
Marr KC,Connors JM,Savage KJ,Goddard KJ,Deyell RJ .2017 .ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol, 10(4) : 849-54.
Benetou DR,Stergianos E,Geropeppa M,Ntinopoulou E,Tzanni M,Pourtsidis A .2018 .Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: A systematic review. Hellenic J Cardiol, 09(3) : 152-64.
'Brien O,Donaldson MM,Balise SS,Whittemore RR,Link AS,MP AS .2009 .Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol, 24(1) : 1232-9.
Inskip PD,Veiga LHS,Brenner AV,Sigurdson AJ,Ostroumova E,Chow EJ .2019 .Hyperthyroidism after radiation therapy for childhood cancer: A report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys, 02(2) : 415-24.
Song KJ,Park JH,Im HJ,Ahn SD .2020 .Survival and long-term toxicities of pediatric Hodgkin lymphoma after combined modality treatment: A single institute experience. Radiat Oncol J, 00346(3) : 198-206.
Jones LW,Liu Q,Armstrong GT,Ness KK,Yasui Y,Devine K .2014 .Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: A report from the childhood cancer survivor study. J Clin Oncol, 56(32) : 3643-50.
Adam M,Bekueretsion Y,Abubeker A,Tadesse F,Kwiecinska A,Howe R .2021 .Clinical characteristics and histopathologicalp Patterns of Hodgkin lymphoma and treatment outcomes at a tertiary cancer center in Ethiopia. JCO Glob Oncol, 10 : 277-88.
Radhakrishnan V,Dhanushkodi M,Ganesan TS,Ganesan P,Sundersingh S,Selvaluxmy G .2016 .Pediatric Hodgkin lymphoma treated at cancer institute, Chennai, India: Longterm outcome. J Glob Oncol, 005314(5) : 545-54.
Belgaumi A,Al-Ko de AA,Khafaga Y,Joseph N,Malik RJ,Siddiqui KS .2009 .Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematol Oncol Stem Cell Ther, 3876(09) : 50038-6.
Hazarika M,Sutnga C,Raj DN,Roy PS,Sarangi SS,Reddy R .2023 .Pediatric Hodgkin s lymphoma: Experience from a tertiary cancer center in North East India. Int J Contemp Pediatrics, 10(2) : 2349-3291.
Palayullakandi A,Trehan A,Jain R,Kumar R,Mittal BR,Kapoor R .2022 .Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting. Pediatr Hematol Oncol, 2044418(7) : 587-99.
Kahn JM,Pei Q,Friedman DL,Kaplan J,Keller FG,Hodgson D .2022 .Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: A retrospective pooled analysis of children s oncology group trials. Lancet Haematol, 3026(21) : 00349-5.
Parambil BC,Narula G,Prasad M,Shah S,Shet T,Shridhar E .2020 .l Clinical pro le and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. Pediatr Blood Cancer, 10(2) : .
0

Citations

0

Downloads

28

Views